Semaglutide vs Tirzepatide: What's the Difference?

If you've been researching GLP-1 medications for weight loss, you've almost certainly encountered both names: semaglutide (the drug behind Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). They're often discussed interchangeably — both weekly injections, both producing significant weight loss, both requiring a prescription. But they are not the same drug, and the differences between them are clinically meaningful.

This guide explains exactly how they differ — in mechanism, in clinical trial outcomes, in side effect profiles, and in who each one tends to suit — drawing on the most current evidence, including the landmark SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in May 2025.

The Core Difference: One Receptor vs Two

Both medications work by mimicking gut hormones that regulate appetite, blood sugar, and metabolism. But they target different receptors — and that difference in mechanism is the root cause of their different performance profiles.

What GIP Adds to the Equation

GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone that works alongside GLP-1 in regulating insulin secretion and fat metabolism. For decades, GIP was considered of limited therapeutic value — until tirzepatide demonstrated that co-activating GIP and GLP-1 receptors simultaneously produces substantially better metabolic outcomes than GLP-1 stimulation alone.^[1]

The GIP receptor is found in adipose (fat) tissue, where it appears to regulate lipid uptake and fat mobilisation. When both receptors are activated together, the combined effect on appetite suppression, satiety signalling, and fat metabolism appears to be synergistic — each mechanism amplifying the other — rather than simply additive. This synergy is the primary mechanistic explanation for tirzepatide's superior weight loss outcomes.

The SURMOUNT-5 Trial: The First Head-to-Head Evidence

For most of the period since tirzepatide's approval, direct comparisons between the two drugs were indirect — based on comparing separate clinical trials conducted in different populations under different conditions. SURMOUNT-5 changed that.

Published in the New England Journal of Medicine in May 2025, SURMOUNT-5 was the first randomised controlled trial to directly compare tirzepatide and semaglutide in the same population, at the same time, under the same conditions. The results were unambiguous.^[2]

Beyond the primary outcome, the secondary endpoints reinforced tirzepatide's superiority. Among participants in the trial, 31.6% of the tirzepatide group achieved at least 25% body weight loss, compared to 16.1% of the semaglutide group — a clinically meaningful difference for patients with significant obesity. Tirzepatide also produced greater reductions in waist circumference across all sub-groups evaluated, including by sex, age, baseline BMI, and presence of metabolic comorbidities.^[2]

One notable finding: weight loss was approximately 6% lower in men than women in both treatment groups — likely contributing to the slightly lower overall weight loss numbers in this trial compared to the larger STEP-1 and SURMOUNT-1 trials, which enrolled proportionally fewer men.

Full Head-to-Head Comparison

Brand Names: Clearing Up the Confusion

Both drugs are sold under multiple brand names depending on the indication — which adds to the confusion for patients trying to understand what they're being prescribed.

A practical note: the same active drug at a higher dose is approved for weight management than for diabetes. Ozempic and Wegovy both contain semaglutide, but Wegovy is approved at a higher dose (2.4mg) specifically for obesity, while Ozempic tops out at 2.0mg for diabetes management. The same distinction applies to Mounjaro and Zepbound.

Cardiovascular Evidence: Where Semaglutide Leads

One of the most clinically significant differences between the two drugs is the current state of cardiovascular evidence. Semaglutide has a substantially longer track record, including the landmark SELECT trial.^[3]

The SELECT trial enrolled over 17,000 adults with obesity and established cardiovascular disease but without diabetes. Participants were randomised to semaglutide 2.4mg or placebo for a mean of 3.3 years. Semaglutide reduced the risk of major adverse cardiovascular events (MACE — a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke) by 20% compared to placebo. This was a landmark finding: it established that the cardiovascular benefits of semaglutide extend beyond blood sugar control, and are partly independent of weight loss itself.

Tirzepatide's SUMMIT trial demonstrated significant improvements in cardiac structure and function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, with meaningful reductions in left ventricular mass and paracardiac adipose tissue. Long-term cardiovascular outcome data comparable to SELECT is still maturing for tirzepatide, and head-to-head cardiovascular comparisons do not yet exist.

For patients with established cardiovascular disease, semaglutide's stronger evidence base currently gives it a clinical advantage in this specific context — though this may shift as tirzepatide's long-term cardiovascular data accumulates.^[4]

Side Effects: More Similar Than Different

Both drugs produce a similar side effect profile, driven by the shared GLP-1 mechanism. The most common adverse events for both are gastrointestinal: nausea, diarrhoea, constipation, and vomiting — particularly during dose escalation. These tend to be most pronounced in the first 4–8 weeks of treatment or following a dose increase, and diminish over time as the body adapts.^[5]

In the SURMOUNT-5 head-to-head trial, overall GI adverse event rates were comparable between the two drugs (approximately 40–50% of participants in both groups reported GI events). However, the rate of GI-related treatment discontinuation was notably lower with tirzepatide (2.7%) than semaglutide (5.6%) — suggesting that while both cause similar GI symptoms, semaglutide patients may find them harder to tolerate long-term.

Tirzepatide produced more frequent injection site reactions than semaglutide, though these were generally mild and did not cause significant discontinuation. Both drugs share the same serious adverse event considerations — pancreatitis, gallbladder disease, and the theoretical thyroid cancer risk that prompts their shared contraindications.

Who Each Drug Tends to Suit Best

Both medications are first-line options for obesity management, and neither is universally superior. The right choice depends on individual clinical circumstances, which should be discussed with a prescribing clinician. That said, some general patterns emerge from the clinical literature:

Shared Contraindications

A Note on Switching Between Drugs

Many clinicians are now seeing patients who have plateaued on semaglutide and are switching to tirzepatide to pursue greater weight loss. The clinical evidence supports this approach — tirzepatide produces meaningful additional weight loss even in patients who have previously used GLP-1 therapy. In real-world data comparing GLP-1 naïve and non-naïve patients, tirzepatide consistently outperformed semaglutide regardless of prior GLP-1 exposure.^[6]

If you are considering a switch, this should always be done under clinical supervision — with appropriate monitoring of the transition period, dose escalation on the new drug, and reassessment of your overall protocol.

Summary

Semaglutide and tirzepatide are both clinically proven, FDA-approved medications that produce meaningful and sustained weight loss. The key differences come down to mechanism, magnitude of weight loss, and cardiovascular evidence.

Tirzepatide's dual receptor mechanism delivers superior weight loss — now confirmed in the SURMOUNT-5 head-to-head trial. Semaglutide's longer track record and SELECT cardiovascular trial data give it a current advantage for patients with established heart disease. Both cause similar GI side effects; tirzepatide appears slightly better tolerated in terms of treatment discontinuation.

Neither drug is the right choice for everyone. The decision belongs to you and your clinician, informed by your health history, your weight loss goals, your cardiovascular risk profile, and your individual tolerance and preferences.